InSphero provides 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology for in vitro testing, enabling pharmaceutical and biotechnological industries to make better preclinical decisions, reduce development costs, and shorten time to market. Its patented 3D cell culture platforms enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumor tissues. The microtissues are used to identify promising drugs and toxic liabilities with greater predictivity at early development stages, helping to develop personalized chemotherapeutic strategies for the treatment of cancer. InSphero's technologies have been validated by the world's largest government institutions and pharmaceutical, chemical, and cosmetics companies, and it has been recognized for its scientific and commercial achievements with a number of national and international awards.